![](https://ml.globenewswire.com/media/YmJhNzkxM2ItMWY1Ny00MDdlLWJhYTQtMzg1NDY3MGQ5MzM3LTEyNTgxMTk=/tiny/Third-Harmonic-Bio.png)
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million …